Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 5/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198959 | 1.00 | AOC3 (0.58) | AOC3TAAR1NPC1RAB9ABCAT2 | |
| Hydrochloric Acid SCHEMBL28129394 | 0.98 | TAAR1 (0.56) | AOC3TAAR1NPC1RAB9ABCAT2 | |
| Hydrochloric Acid SCHEMBL28129392 | 0.98 | TAAR1 (0.56) | AOC3TAAR1NPC1RAB9ABCAT2 | |
| SCHEMBL17186316 | 0.86 | AOC3 (0.51) | AOC3TAAR1NPC1RAB9ABCAT2 | |
| Hydrochloric Acid SCHEMBL17186414 | 0.85 | TAAR1 (0.50) | AOC3TAAR1NPC1RAB9ABCAT2 | |
| Hydrochloric Acid SCHEMBL30496738 | 0.84 | TAAR1 (0.49) | AOC3TAAR1NPC1RAB9ABCAT2 | |
| SCHEMBL7423517 | 0.82 | AOC3 (0.55) | AOC3TAAR1NPC1RAB9ABCAT2 | |
| SCHEMBL2432247 | 0.81 | BCAT2 (0.66) | AOC3TAAR1NPC1RAB9ABCAT2 | |
| SCHEMBL1605295 | 0.81 | AOC3 (0.58) | AOC3TAAR1NPC1RAB9ABCAT2 | |
| SCHEMBL1605547 | 0.81 | AOC3 (0.58) | AOC3TAAR1NPC1RAB9ABCAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-111848494-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-106458868-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009087395-A1 | WEIGHT REDUCING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009087395-A1 | WEIGHT REDUCING COMPOUNDS | UNIVERSITY OF STRATHCLYDE (GB) | 2009-07-16 | — | — | WO | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | AOC3 4592/4885TAAR1 4813/4885NPC1 2485/4885 |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | AOC3 4592/4885TAAR1 4813/4885NPC1 2485/4885 |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | AOC3 4592/4885TAAR1 4813/4885NPC1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.